Nephrology Medical News about Chronic Kidney Disease

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

5. Debunking Myths in the US Healthcare System

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Mineralocorticoid Receptor Blockers and Chronic Kidney Disease
Clinical Journal of the American Society of Nephrology, 10/08/09

Jain G et al. – The authors review the role of aldosterone in end–organ damage, the rationales for using MRBs as adjuncts to angiotensin–converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in treating CKD, and the adverse effects that may occur when these agents are used in combination. Suggestions are included for avoiding serious adverse events in CKD patients treated with MRBs. There is a clearly defined need for prospective outcome studies focused on cardiovascular mortality as well as progression of CKD in patients treated with MRBS and other inhibitors of the RAAS.

<< Previous
Premature deaths attributable to blood pressure in China: a...

Next >>
Assessing acid–base disorders